文献詳細
特集 第62回日本臨床眼科学会講演集(3)
原著
文献概要
要約 目的:近視性脈絡膜新生血管に対するベバシズマブ硝子体内投与の効果の報告。対象と方法:近視性脈絡膜新生血管がある16例16眼を対象とした。男性2例,女性14例で,年齢は32~80歳(平均62歳)である。屈折は全例が-6D以上であった。視力はlogMARで評価した。結果:1.25mgベバシズマブを1~4回(平均1.3回)投与し,14例(88%)で新生血管が非活性化した。新生血管が瘢痕化したあと,1眼で視力が0.3以上悪化した。結論:近視性脈絡膜新生血管に対しベバシズマブの硝子体内投与は有効であるが,病巣周囲の網脈絡膜萎縮の進行により視力が悪化することがある。
参考文献
1)Ghafour IM, Allan D, Foulds WS:Common causes of blindness and visual handicap in the West of Scotland. Br J Ophthalmol 67:209-213, 1983
2)Sperduto RD, Seigel D, Robers J et al:Prevalence of myopia in the United States. Arch Ophthalmol 101:405-407, 1983
3)中江公裕・増田寛次郎・妹尾 正・他:わが国における視覚障害の現状.厚生労働省難治性疾患克服研究事業.網膜脈絡膜・視神経萎縮症に関する研究班平成17年度研究報告書.263-267,2006
4)Avila MP, Weiter JJ, Jalkh AE et al:Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573-1581, 1984
5)Yoshida T, Ohno-Matsui K, Yasuzumi K et al:Myopic choroidal neovascularization. A 10-year follow-up. Ophthalmology 110:1297-1305, 2003
6)Ohno-Matsui K, Yoshida T, Futagami S et al:Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathologic myopia. Br J Ophthalmol 87:570-573, 2003
7)Verteporfin in Photodynamic Therapy(VIP)Study Group:Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin:1-year results of a randomized clinical trial-VIP report no.1. Ophthalmology 108:841-852, 2001
8)Verteporfin in Photodynamic Therapy(VIP)Study Group:Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia:2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667-673, 2003
9)Yamamoto I, Rogers AH, Reichel E et al:Intravitreal bevacizumab(Avastin)as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol 91:157-160, 2007
10)Sakaguchi H, Ikuno Y, Gomi F et al:Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165, 2007
11)Chan WM, Lai TYY, Liu DTL et al:Intravitreal bevacizumab(Avastin)for myopic choroidal neovascularization:1-year results of a prospective pilot study. Br J Ophthalmol(in press)
12)Ikuno Y, Sayanagi K, Soga K et al:Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia:one-year results. Am J Ophthalmol(in press)
13)大野京子:近視性脈絡膜新生血管.眼科 50:707-716,2008
14)Hurwitz H, Fehrenbacher L, Novotny W et al:Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
15)高橋 浩:臨床医の知るべき眼組織関連細胞生物学―抗VEGF療法を題材として.日眼会誌 112:647-658,2008
16)Nguyen QD, Sham AM, Hafiz G et al:Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol 145:257-266, 2008
17)Soubrane G, Coscas G:Choroidal neovascular membrane in degenerative myopia. In:Stephen J(ed):Medical Retina. vol. 2. New York, Mosby, 2006
18)Paavonenn K, Puolakkainen P, Jussila L et al:Vascular endothelial growth factor receptor-3 in lymphagiogenesis in wound healing. Am J Pathol 156:1499-1504, 2000
19)Kuvanta A, Algvere PV, Berglin L et al:Subfoveal fibrovascular membranes in age-related macular degeneration expresss vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929-1934, 1996
20)Hayashi K, Ohno-Matsui K, Teramukai S et al:Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients:comparison with nontreated controls. Am J Ophthalmol 145:518-526, 2008
21)Fung AE, Rossenfeld PJ, Reichel E:The international intravitreal bevacizumab safety survey:using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349, 2006
掲載誌情報